Menü
Microsoft selbst warnt vor der Verwendung von Internet Explorer, da er nicht mehr den neuesten Web- und Sicherheitsstandards entspricht. Wir können daher nicht garantieren, dass die Seite im Internet Explorer in vollem Umfang funktioniert. Nutze bitte Chrome oder Firefox.

Suchergebnisse

Adma Biologics (ADMA) Exceeds Market Returns: Some Facts to Consider
Adma Biologics (ADMA) Exceeds Market Returns: Some Facts to Consider

Adma Biologics (ADMA) closed at $10.65 in the latest trading session, marking a +1.53% move from the prior day. This move outpaced the S&P 500's daily gain of 0.8%. Meanwhile, the Dow experienced a

Adma Biologics (ADMA) Laps the Stock Market: Here's Why
Adma Biologics (ADMA) Laps the Stock Market: Here's Why

In the latest close session, Adma Biologics (ADMA) was up +1.22% at $9.95. The stock's performance was ahead of the S&P 500's daily gain of 0.62%. Elsewhere, the Dow gained 0.58%, while the

Will Lead Drug Asceniv Fuel ADMA's Top-Line Growth in 2026?
Will Lead Drug Asceniv Fuel ADMA's Top-Line Growth in 2026?

ADMA Biologics ADMA markets plasma-derived biologics for the treatment of immune deficiencies and the prevention of certain infectious diseases.

Asceniv, its lead product, is a plasma-derived IVIG

Adma Biologics (ADMA) Stock Declines While Market Improves: Some Information for Investors
Adma Biologics (ADMA) Stock Declines While Market Improves: Some Information for Investors

In the latest trading session, Adma Biologics (ADMA) closed at $9.01, marking a -1.53% move from the previous day. The stock fell short of the S&P 500, which registered a gain of 2.91% for the day

Is ADMA Poised for Margin Growth and Supply Expansion in 2026?
Is ADMA Poised for Margin Growth and Supply Expansion in 2026?

ADMA Biologics ADMA markets plasma-derived biologics for the treatment of immune deficiencies and the prevention of certain infectious diseases.

Gross margin improved to 57.4% in 2025 from 51.5% in

ADMA Crashes 42.5% YTD: Right Time to Buy the Stock?
ADMA Crashes 42.5% YTD: Right Time to Buy the Stock?

ADMA Biologics’ ADMA shares have plunged 42.5% year to date against the industry’s growth of 1.6%.  The stock has also underperformed the sector and the S&P 500 in this time frame.

Much of this

Cansino Biologics Inc.

WKN: A2PGFW / Name: Cansino Biologics Inc. / Aktie / ? /

?
2,79 %

Mustgrow Biologics Corp.

WKN: A2PNS7 / Name: Mustgrow Biologics Corp. / Aktie / ? /

?
0,00 %

Pure Biologics S.a.

WKN: A2N9NP / Name: Pure Biologics S.a. / Aktie / ? /

?
2,97 %

Innovent Biologics, Inc.

WKN: A2N7N8 / Name: Innovent Biologics / Aktie / Small Cap /

9,20 €
-1,60 %

Abcellera Biologics Inc.

WKN: A2QKXS / Name: Abcellera Biologics Inc. / Aktie / ? /

3,27 €
1,26 %

Heat Biologics Inc.

WKN: A2QJR8 / Symbol: HBTX / Name: Heat Biologics / Aktie / Biotechnologie & medizinische Forschung / Micro Cap /

0,069 €
-24,86 %

Wuxi Biologics Cayman Inc.

WKN: A2QJCN / Name: Wuxi Biologics / Aktie / Mid Cap /

4,03 €
-1,84 %

Wuxi Biologics (cayman) Inc.

WKN: A2PQ3Q / Name: Wuxi Biologics (cayman) Inc. / Aktie / ? /

?
3,25 %

Synthetic Biologics Inc.

WKN: A3DMG6 / Symbol: SYN / Name: Synthetic Biologics / Aktie / Biotechnologie & medizinische Forschung / Small Cap /

0,12 €
-0,68 %

Fibrobiologics Inc.

WKN: A3EP67 / Name: Fibrobiologics Inc. / Aktie / ? /

0,16 €
-14,14 %

Theriva Biologics Inc.

WKN: A40MGC / Name: Theriva Biologics Inc. / Aktie / ? /

2,42 €
-

Fibrobiologics Inc.

WKN: A426UV / Name: Fibrobiologics Inc. / Aktie / ? /

3,74 €
-